NCT03543358 2021-01-05A Long-Term Study of Rovalpituzumab TesirineAbbViePhase 2 Completed3 enrolled 6 charts
NCT01901653 2018-08-09Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung CancerStemcentrxPhase 1/2 Completed82 enrolled 28 charts